The FDA's controversial fast-track drug approval plan sparks concerns and legal questions.
Washington is abuzz with the Food and Drug Administration's ambitious plan to accelerate drug approvals, championed by President Trump's administration. This move has triggered a wave of anxiety and uncertainty within the agency, as many fear it might compromise the rigorous legal, ethical, and scientific standards that have long safeguarded the public from unsafe or ineffective medications.
The program, spearheaded by FDA commissioner Marty Makary, has left employees reeling, especially those already grappling with layoffs, buyouts, and leadership changes. Speaking anonymously, seven current and former staffers revealed their concerns to the Associated Press.
But here's where it gets controversial: The FDA's top echelons are grappling with a critical question: Who holds the legal authority to greenlight drugs under the Commissioner's National Priority Voucher program? This program promises lightning-fast approvals, sometimes within a month, for drugs deemed vital to U.S. national interests.
Historically, FDA drug approvals have been the domain of review scientists and their supervisors, not political appointees. Yet, drug reviewers claim they've been left in the dark about the new program's inner workings. Adding to the intrigue, some reviewers working on a highly anticipated anti-obesity pill were instructed to bypass certain regulatory steps to meet aggressive deadlines set by top officials.
And this is the part most people miss: The FDA already boasts the world's fastest drug review process, typically taking 6 to 10 months. Experts argue that condensing this process to one or two months is scientifically unprecedented. Dr. Aaron Kesselheim, a Harvard Medical School professor, asserts that the FDA lacks the resources to conduct its usual detailed review within such a tight timeframe.
Reuters reported that the FDA has delayed the review of two drugs in the program due to safety concerns, including a patient death. Despite this, the Health and Human Services spokesman, Andrew Nixon, defends the program, emphasizing its commitment to rigorous scientific review and the delivery of effective treatments.
The program has found favor in the White House, where President Trump has announced pricing concessions from drugmakers, often accompanied by FDA vouchers for companies agreeing to lower prices. For instance, when Eli Lilly and Novo Nordisk pledged to reduce prices on obesity drugs, FDA staffers had to hastily vet vouchers for both companies ahead of Trump's press conference.
This has raised eyebrows among observers, who worry that FDA drug reviews, once strictly objective, are now vulnerable to political influence. Paul Kim, a former FDA attorney, describes the application process as opaque and susceptible to politicization.
Controversy alert: The program's legal foundation is shaky, as it hasn't been formally established in federal rules and regulations. The FDA already has several programs to expedite drug reviews, all approved by Congress and backed by agency regulations. In contrast, the voucher program's details are largely limited to an agency website, with drugmakers applying via a 350-word statement of interest.
The situation has become more complex as agency leaders like Dr. Vinay Prasad, the FDA's top medical officer, have taken to directly contacting drugmakers about vouchers. This has left FDA staffers grappling with basic procedural questions, such as how to award a voucher to a company that didn't explicitly request one.
Nixon maintains that voucher submissions are evaluated by a senior multidisciplinary committee led by Prasad. However, legal concerns prompted the FDA's former drug director, Dr. George Tidmarsh, to refuse to sign off on approvals under the program, according to sources. Tidmarsh resigned in November following a lawsuit unrelated to the voucher program.
After Tidmarsh's departure, the responsibility fell to Dr. Sara Brenner, the FDA's principal deputy commissioner, who also declined due to legal concerns. Currently, Dr. Mallika Mundkur, the deputy chief medical officer working under Prasad, is handling this role.
Final approval of a drug carries significant legal risks, as it certifies the medication's safety and effectiveness according to FDA standards. If unforeseen safety issues arise later, both the agency and individual staff members could face investigations or lawsuits.
Traditionally, FDA drug office directors make approval decisions in consultation with review teams. Under the voucher program, however, approval is determined by a committee vote of senior agency leaders, excluding staff reviewers. Dr. Kesselheim, who is also a lawyer and medical researcher, calls this a complete reversal of the usual process, which is typically led by scientists deeply engaged with the data.
Not everyone is critical of the program. Dan Troy, the FDA's former top lawyer under President Bush, argues that federal law grants the commissioner broad powers to reorganize drug review processes. However, he cautions that the program's longevity is uncertain due to its lack of formal codification.
The voucher program has grown significantly, with 18 vouchers awarded and more under consideration, following aggressive promotion by FDA officials. This expansion strains the agency's drug center, which has seen a 20% staff reduction in the past year due to retirements, buyouts, and resignations.
When Makary introduced the program, concerns arose about his unprecedented power in selecting beneficiary companies. Initially, it was stated that career staffers would nominate drugs, and some early recommendations came from FDA reviewers who deliberately chose drugs that could be quickly vetted.
However, sources reveal that selection decisions are increasingly made by Prasad or other senior officials, sometimes without FDA staff knowledge. In one instance, FDA reviewers learned from GlaxoSmithKline representatives that Prasad had contacted the company about a voucher.
Makary's accessibility is limited, as he reportedly doesn't use a government email account for official business, breaking with established protocol.
The plot thickens: Once vouchers are awarded, drugmakers sometimes interpret the review timeline differently, causing further confusion and anxiety among staff. In the ongoing review of Eli Lilly's anti-obesity pill, company executives initially expected approval within two months, a timeline that alarmed FDA reviewers due to the exclusion of the standard 60-day prefiling period.
Lilly pushed for a quicker filing turnaround, and the agency eventually agreed to a two-week period. Lilly's CEO, David Ricks, publicly stated his expectation of FDA approval in the second quarter. Nixon, while declining to comment on Lilly's review specifics, asserted that reviewers can adjust timelines as needed.
Staffers were urged to keep the application moving, despite apparent gaps in data about the drug's chemistry. When reviewers raised concerns, a senior FDA official reportedly instructed them to overlook regulations if the science was sound, a stark departure from standard FDA review practices.
Former reviewers and experts emphasize that skipping review steps could backfire for drugmakers if future FDA leaders question a drug's vetting process. Dr. Kesselheim and other experts predict that the program's fate is tied to the current administration, and they hope for a return to scientifically and legally sound principles.
The FDA's fast-track program has sparked intense debate, and the question remains: Is it a necessary innovation or a risky shortcut? What do you think? Share your thoughts in the comments below.
